GNRH1 and Familial prostate cancer: Herein, it has been demonstrated that three GnRH antagonists developed for clinical purposes, such as prevention of premature ovulation and prostate cancer therapy [37], have different potencies in inhibiting hormone-dependent intracellular signaling in vitro.